13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

8 trials found

diseases per page:

Showing 1 to 8 of 8 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-020315-36-IT (EUCTR)	05/10/2011	27/12/2011	A study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Scl ...	A Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety o ...	Relapsing Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relap ...	Product Name: Ocrelizumab Product Code: RO4964913 INN or Proposed INN: OCRELIZUMAB Trade Name: Rebif INN ...	ROCHE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	469		Colombia;Turkey;Ireland;Italy;Sweden;Brazil;United Kingdom;Russian Federation;Canada;Ukraine;Belarus ...
2	NCT01412333 (ClinicalTrials.gov)	September 20, 2011	8/8/2011	A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif)in Participants With Relapsing M ...	A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety o ...	Relapsing Multiple Sclerosis	Drug: Interferon beta -1a;Drug: Ocrelizumab-matching placebo;Drug: Ocrelizumab;Drug: Interferon beta - ...	Hoffmann-La Roche	NULL	Completed	18 Years	55 Years	All	835	Phase 3	United States;Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czechi ...
3	NCT01247324 (ClinicalTrials.gov)	August 31, 2011	23/11/2010	A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif)in Participants With Relapsing M ...	A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety o ...	Relapsing Multiple Sclerosis	Drug: Interferon beta -1a;Drug: Ocrelizumab-matching placebo;Drug: Ocrelizumab;Drug: Interferon beta - ...	Hoffmann-La Roche	NULL	Completed	18 Years	55 Years	All	821	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czechia;Estonia;Finland;Fran ...
4	NCT01285401 (ClinicalTrials.gov)	February 2011	26/1/2011	Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multi ...	A Three Arm, Randomized, Double Blind, Placebo Controlled, Multicenter, Phase II Study to Evaluate t ...	Relapsing-Remitting Multiple Sclerosis	Drug: VigantOL oil plus interferon beta-1a (Rebif);Drug: Placebo plus interferon beta -1a(Rebif);Biolo ...	Merck KGaA	NULL	Completed	18 Years	55 Years	All	260	Phase 2	Austria;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerla ...
5	NCT01101776 (ClinicalTrials.gov)	January 2010	8/4/2010	Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients ...	Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients ...	Multiple Sclerosis	Drug: Interferon beta -1a (Rebif)	Merck KGaA	Merck Serono Australia Pty Ltd	Completed	18 Years	N/A	Both	49	N/A	Australia
6	EUCTR2007-001162-32-IT (EUCTR)	06/08/2008	14/07/2008	A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- ...	A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- ...	Relapsing Remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10048393;T ...	Trade Name: MABCAMPATH INN or Proposed INN: Alemtuzumab Trade Name: REBIF INN or Proposed INN: Interfer ...	Genzyme Corporation	NULL	Not Recruiting			Female: yes Male: yes	573	Phase 3	France;Czech Republic;Poland;Spain;Belgium;Denmark;Austria;Germany;Netherlands;United Kingdom;Italy; ...
7	NCT01142466 (ClinicalTrials.gov)	December 2005	10/6/2010	A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compar ...	Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Wee ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta -1a (Rebif)	Merck KGaA	Gesellschaft für Therapieforschung mbH	Completed	18 Years	60 Years	All	30	Phase 4	NULL
8	NCT01142557 (ClinicalTrials.gov)	June 2004	10/6/2010	An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the T ...	Therapy of the Chronic Multiple Sclerosis With Interferon-beta 1a (Rebif®)	Multiple Sclerosis	Drug: Interferon beta -1a (Rebif)	Merck KGaA	Gesellschaft für Therapieforschung mbH	Completed	N/A	N/A	Both	522	N/A	Germany

First Previous1Next Last